Krystal Biotech (NASDAQ:KRYS) Upgraded by Zacks Investment Research to “Buy”

Krystal Biotech (NASDAQ:KRYSGet Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, Zacks.com reports. The firm presently has a $71.00 target price on the stock. Zacks Investment Research‘s target price indicates a potential upside of 6.67% from the stock’s previous close.

According to Zacks, “Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. “

A number of other brokerages have also commented on KRYS. The Goldman Sachs Group decreased their price objective on Krystal Biotech from $125.00 to $93.00 and set a “buy” rating on the stock in a research report on Tuesday, March 1st. Guggenheim reduced their target price on Krystal Biotech from $114.00 to $101.00 in a report on Tuesday, March 29th. Bank of America started coverage on Krystal Biotech in a report on Tuesday, January 18th. They set a “buy” rating and a $110.00 target price on the stock. Finally, HC Wainwright dropped their price target on Krystal Biotech from $124.00 to $107.00 and set a “buy” rating on the stock in a research note on Monday, February 28th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Krystal Biotech presently has a consensus rating of “Buy” and a consensus price target of $96.50.

NASDAQ KRYS opened at $66.56 on Thursday. The stock has a 50-day simple moving average of $66.53 and a 200 day simple moving average of $62.42. The stock has a market capitalization of $1.68 billion, a PE ratio of -21.33 and a beta of 0.99. Krystal Biotech has a twelve month low of $38.86 and a twelve month high of $102.99.

Krystal Biotech (NASDAQ:KRYSGet Rating) last issued its earnings results on Monday, February 28th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.76) by ($0.18). As a group, sell-side analysts predict that Krystal Biotech will post -4.07 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of KRYS. Confluence Wealth Services Inc. bought a new position in Krystal Biotech in the 4th quarter valued at about $25,000. Advisor Group Holdings Inc. purchased a new stake in shares of Krystal Biotech during the 3rd quarter worth approximately $32,000. Widmann Financial Services Inc. purchased a new stake in shares of Krystal Biotech during the 4th quarter worth approximately $34,000. Lazard Asset Management LLC grew its stake in Krystal Biotech by 21.0% in the 4th quarter. Lazard Asset Management LLC now owns 1,272 shares of the company’s stock valued at $88,000 after buying an additional 221 shares in the last quarter. Finally, Point72 Hong Kong Ltd grew its stake in Krystal Biotech by 5,072.7% in the 3rd quarter. Point72 Hong Kong Ltd now owns 2,276 shares of the company’s stock valued at $119,000 after buying an additional 2,232 shares in the last quarter. Institutional investors and hedge funds own 76.57% of the company’s stock.

Krystal Biotech Company Profile (Get Rating)

Krystal Biotech, Inc, a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa.

Recommended Stories

Get a free copy of the Zacks research report on Krystal Biotech (KRYS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.